GitLab stock whipsaws: GTLB holds gains in premarket after 13% surge
23 January 2026
2 mins read

GitLab stock whipsaws: GTLB holds gains in premarket after 13% surge

New York, Jan 23, 2026, 05:04 ET — Premarket

  • Before the bell, GitLab shares gained roughly 0.5%, trading near $37.60.
  • The stock surged 12.8% in the previous session, rebounding sharply from a fresh 52-week low.
  • Recent SEC filings reveal that GitLab’s incoming CFO and CTO do not hold any beneficial ownership in the company’s securities.

GitLab Inc shares (GTLB.O) ticked up slightly in premarket trading on Friday, building on a strong bounce that pushed the DevSecOps software company over 12% higher the day before. The stock hovered near $37.60, up roughly 0.5%. (Google)

The move is significant since GitLab has hovered near its lows, and Thursday’s late-session rebound came suddenly, even by recent measures. Traders will be looking to see if the bounce sticks when U.S. cash trading kicks off or if it’s just a brief pause after the drop.

On Thursday, GitLab’s shares bounced sharply, hitting a low around $32.92—a fresh 52-week low—before rallying to an intraday high of $37.53. The stock closed at $37.40, with trading volume exceeding its recent average, data showed. (Investing)

New filings have once again highlighted management turnover, a lingering issue since late 2025, though Thursday’s rally lacked a clear catalyst.

GitLab’s new CFO, Jessica P. Ross, filed a Form 3 insider ownership disclosure showing she currently owns no securities. The filing is dated Jan. 15 and was signed on Jan. 22. (Sec)

A separate Form 3 filed for GitLab’s new chief technology officer, Sivaprasad Padisetty, showed the same “no securities are beneficially owned” disclosure. The form is dated Jan. 15 and was signed on Jan. 22. (Sec)

GitLab announced earlier this month that Siva Padisetty will step in as CTO on Jan. 15, taking over from Sabrina Farmer. Farmer has stepped down but will stay on as an adviser until Jan. 31. CEO Bill Staples dubbed Padisetty “the engineer’s CTO,” while Padisetty emphasized that the AI opportunity goes beyond just speeding up code. (Gitlab)

In its most recent quarterly filing from December, the company reported $244.4 million in revenue for the quarter ending Oct. 31, marking a 25% increase compared to the same period last year. It also provided guidance for both the current quarter and the full fiscal year. (Sec)

GitLab offers tools for building, securing, and shipping software. In this space, customers demand clearer returns from AI features but remain budget-conscious. Competitors include Microsoft-owned GitHub in code collaboration and various enterprise software companies providing developer tools.

That rebound might not hold. One choppy session won’t answer the persistent doubts investors have — can GitLab reignite growth, retain its biggest clients, and maintain pricing power while rivals roll out more comprehensive bundled offerings?

Traders are now waiting on an official date for GitLab’s next earnings release. While market calendars peg the report around March 2, the company hasn’t confirmed that yet. (Marketbeat)

Stock Market Today

  • Oric Pharmaceuticals Shares Poised for 74% Upside as Biotech Innovation Draws Investor Attention
    January 23, 2026, 8:13 AM EST. Oric Pharmaceuticals (NASDAQ: ORIC) is gaining investor interest with a potential 74% upside from its current $12.05 share price, backed by partnerships with Pfizer, Bayer, and Johnson & Johnson. The clinical-stage biotech focuses on therapies addressing cancer treatment resistance, advancing candidates like ORIC-114 and ORIC-944 through early-stage trials. Despite a $1.17 billion market cap, Oric reports a negative EPS of -1.71 and free cash flow of -$70.7 million, reflecting typical high-risk biotech dynamics. With no dividends and a neutral RSI, stock momentum shows cautious optimism. Analysts rate ORIC with 14 buys and project a $21 average target price, suggesting substantial growth for investors able to tolerate the sector's inherent uncertainties.
Meta stock steadies before the bell after a 5.7% pop — here’s what’s driving META now
Previous Story

Meta stock steadies before the bell after a 5.7% pop — here’s what’s driving META now

Abbott stock sank 10% on earnings — what traders watch before the bell
Next Story

Abbott stock sank 10% on earnings — what traders watch before the bell

Go toTop